The Law Offices of Frank R. Cruz announces an investigation of Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI) on behalf of investors concerning the Company’s possible violations of federal securities laws.

What Is The Investigation About?
On February 25, 2025, Maravai disclosed that it is postponing its previously announced earnings release and would be unable to timely file its annual financial report. The Company explained it requires additional time to “complete its assessment of a potential non-cash impairment charge related to goodwill associated with its previous acquisition of Alphazyme LLC,” and to “assess an error . . . that resulted in approximately $3.9 million in revenue being recorded in the final week of the second quarter of 2024 upon shipment when it should have been recorded in the first week of the third quarter of 2024 upon receipt by the customer.”

On this news, Maravai’s stock price fell as much as 26% during intraday trading on February 25, 2025, thereby injuring investors.